CFI-400945 is an orally available fumarate salt form of CFI-400945, a polo-like kinase 4 (PLK4) inhibitor with potential antineoplastic activity. Upon oral administration, polo-like kinase 4 inhibitor CFI-400945 selectively inhibits PLK4, which results in the disruption of mitosis and the induction of apoptosis. PLK4 inhibition also prevents cell division and inhibits proliferation of PLK4-overexpressing tumor cells. PLK4, a member of the polo family of serine/threonine kinases overexpressed in a variety of cancer cell types, plays a crucial role in the regulation of centriole duplication during the cell cycle.
Chemical | |
---|---|
CAS Num | 1616420-30-4 (CFI-400945 fumarate) |
Chemical Formula | C37H38N4O7 |
Molecular Weight | 650.72 |
IUPAC Chemical Name | (1R,2S)-2-(3-((E)-4-(((2S,6R)-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate |
Elemental Analysis | C, 68.29; H, 5.89; N, 8.61; O, 17.21 |
Synonym | CFI400945; CFI 400945; CFI-400945; CFI-400945 fumarate. |
Solubility | Soluble in DMSO, not in water |
SMILES Code | O=C(NC1=C2C=C(C=C1)OC)[C@@]32[C@@H](C3)C4=CC5=C(C(/C=C/C6=CC=C(C=C6)CN7C[C@@H](O[C@@H](C7)C)C)=NN5)C=C4.O=C(O)/C=C/C(O)=O |
Biological | |
Targets and Effects | N/A |
Pathways | Apoptosis |
Physical | |
Appearance | Solid powder |
Purity | >98% (or refer to the Certificate of Analysis) |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
Storage Condition | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Shelf Life | >2 years if stored properly |
Anba Pharma Company
3-H Gill Street, Suite 300
Woburn, MA 01801
United State
Tel: 1+610-883-0668
Email: sales@AnbaPharma.com